Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer

Christopher Grant; Misako Nagasaka

doi:10.1016/j.ctrv.2024.102724

Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer

Cancer Treat Rev. 2024 May:126:102724. doi: 10.1016/j.ctrv.2024.102724. Epub 2024 Mar 27.

Authors

Christopher Grant¹, Misako Nagasaka²

Affiliations

¹ Department of Medicine, University of California Irvine Medical Center, Orange CA, USA.
² Department of Medicine, University of California Irvine Medical Center, Orange CA, USA; Division of Hematology and Oncology, Department of Medicine, University of California Irvine Medical Center, Orange CA, USA. Electronic address: [email protected].

PMID: 38636443
DOI: 10.1016/j.ctrv.2024.102724

Abstract

Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with EGFR and ALK alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with EGFR-TKI monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials' potential benefits, challenges, and future directions in the field.

Keywords: EGFR-mutant; NEOADAURA; Neoadjuvant targeted therapy; Osimertinib; Perioperative targeted therapy.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / pathology
ErbB Receptors* / antagonists & inhibitors
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / pathology
Neoadjuvant Therapy*
Protein Kinase Inhibitors* / therapeutic use

Substances

ErbB Receptors
Protein Kinase Inhibitors
EGFR protein, human